Our Key Therapeutic Areas
We have strategically selected Oncology, Inflammatory Disease, and Neurodegenerative Disease (NDD)
as our primary therapeutic areas based on the significant demand for innovative treatments in these fields.
By implementing this selection and focus strategy, we will significantly enhance our chances of success in global new drug development endeavors.
Our Platform Technology
Dong-A ST, as a traditional small molecule-based new drug development company,
is also focusing on innovative platform technology research to develop new drugs, biopharmaceuticals, and improved drugs.
We aspire to be a global leader in new drug development. To achieve this vision, we are focusing on innovative platform technology research in various domains.
This includes advancing TPD (Targeted Protein Degradation) in small molecule development, pioneering multi-specific antibodies and ADCs in biologics,
and revolutionizing the improved drug field with peptide oral delivery.
SMALL MOLECULE
- AI-driven drug discovery
- Fragment-based drug discovery
- Targeted Protein Degradation (TPD)
Incrementally Modified Drugs (IMDs)
- BA Enhancement
- Controlled Release
- Dosage Form Change
- Fixed Dose Combination